David James Le Count

David James Le Count is a notable inventor based in Macclesfield, GB. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that act as 5-hydroxytryptamine antagonists. With a total of 6 patents to his name, his work has implications for various therapeutic applications.

Latest Patents

Le Count's latest patents include innovative quinoline derivatives. These compounds are characterized by specific formulas where A stands for the radical --(CH.sub.2).sub.2 --, which may be substituted by one or two (1-2C)alkyl radicals. Additionally, Q can represent an oxygen or sulphur atom, while R.degree. denotes a (1-4C)alkyl, (1-4C)alkoxy, or cyclopropyl radical. His patents also cover processes for manufacturing these compounds and pharmaceutical compositions that include them as active ingredients.

Career Highlights

David James Le Count is currently associated with Imperial Chemical Industries Limited, a company known for its advancements in chemical manufacturing and innovation. His work has been pivotal in developing pharmaceutical compositions that utilize his patented compounds, enhancing their therapeutic efficacy.

Collaborations

Throughout his career, Le Count has collaborated with esteemed colleagues such as Christopher John Squire and Robert J Pearce. These partnerships have fostered a collaborative environment that has led to significant advancements in their respective fields.

Conclusion

David James Le Count's contributions to pharmaceutical chemistry through his innovative patents and collaborations highlight his role as a key inventor in the industry. His work continues to influence the development of new therapeutic agents.